Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Intellia Therapeutics
Biotech
Intellia stock sinks on gene therapy patient's raised enzymes
Intellia’s stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but analysts are keeping faith.
James Waldron
May 29, 2025 9:15am
Intellia cuts 27% of staff as it takes ax to pipeline
Jan 10, 2025 4:00am
Intellia, Alnylam post data on contrasting cardiomyopathy ideas
Nov 18, 2024 7:40am
Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks
Oct 24, 2024 8:55am
Intellia doesn't need to re-dose NTLA-2001. But it can be done
Jun 25, 2024 3:31pm
Intellia showcases durability of one-and-done HAE option
Jun 2, 2024 8:00am
